Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

UNKNOWN × Triple Negative Breast Neoplasms × lobaplatin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 1

Interventions

Epirubicin 4 Paclitaxel 3 Cyclophosphamide 3 Carboplatin 3 anlotinib 2 Capecitabine 2 pirarubicin 1 lobaplatin 1 eribulin 1 Zoledronic Acid 1 Granulocyte Colony-Stimulating Factor 1 Etoposide 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05546255 2022-09-19

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

ChineseAMS

Phase 2 Unknown

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡